Glenmark Pharmaceuticals News

Glenmark US Unit Launches Vancomycin Hydrochloride Injection

Glenmark Pharmaceuticals Inc., USA launches Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial, targeting a market with annual sales of ~$37.9 million.

Glenmark Gets FDA Nod for Progesterone Inserts

Glenmark Pharmaceuticals receives U.S. FDA approval for 100 mg progesterone vaginal inserts, targeting a market worth approximately $59.20 million annually in drug sales.

Glenmark Gets FDA Nod for Progesterone Inserts

Glenmark Pharmaceuticals receives U.S. FDA approval for 100 mg progesterone vaginal inserts, targeting a market worth approximately $59 million annually in drug sales.

Glenmark Takes Direct Control of RYALTRIS® in US Market

Glenmark Pharmaceuticals announces strategic shift to direct commercialization and distribution of RYALTRIS® nasal spray in the US, marking expansion of its innovative portfolio with first innovative product in American market.